Head-to-head · WeighScore
June Health vs MyStart Health
By GLP-1 ScorecardUpdated
Score comparison
June Health has the higher recorded score — 63/100 to 61.3/100, but only just.
June Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. June Health is a direct-to-consumer telehealth storefront selling compounded GLP-1 medication for weight loss, alongside peptide, hormone, and hair-loss programs, all delivered online with no office visits. MyStart Health is close behind and may still be the better fit — see the factor split below.
Before you choose
Before comparing the headline prices, the June Health review and the MyStart Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, June Health vs No BS RX and MEDGm vs MyStart Health compare each of them with another graded program, and the list of alternatives to June Health ranks the programs closest to June Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Oak review covers one graded close to these two, at 63.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | June Health | MyStart Health |
|---|---|---|
| WeighScore | 63/100 | 61.3/100 |
| Grade | C | C |
| Site position | #283 | #324 |
| Semaglutide | From $279/mo for injections (tablets from $187/mo; compounded) | $299/mo (all doses, compounded) |
| Tirzepatide | From $409/mo for injections (tablets from $249/mo; compounded) | $299/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Offers both injectable and oral compounded semaglutide and tirzepatide
- Semaglutide injections from $279/mo or tablets from $187/mo; tirzepatide injections from $409/mo or tablets from $249/mo
- Full per-dose price list published on-site with no signup required to view it
- Provider consult ('licensed clinician evaluation') is bundled into the displayed price
- Free discreet shipping advertised with 2-3 day delivery
What to consider
- No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
- No LegitScript seal or other pharmacy-verification badge found anywhere on the site
- Legal entity, prescribing medical group, and compounding pharmacy partner are not named
- Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
- Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
FDAWarning letter issued to Matthew Stern, CEO MyStart Health LLC. in September 2025. See the FDA warning-letter database.
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
What to consider
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- FDA issued Matthew Stern, CEO MyStart Health LLC. a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.